Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04912024 · ClinicalTrials.gov registry record
Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
A clinical trial, sponsored by Outset Medical.
- Completed
- Registry status
- 458
- Enrollment target
NCT04912024 is a clinical trial that has completed, run by Outset Medical. The registered enrollment target is 458 participants.
The verdict
NCT04912024 has completed, sponsored by Outset Medical.
- COMPLETED
- Registry status
- 458 participants
- Enrollment target
Study Summary
Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
Interventions
- DEVICE Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
- DEVICE Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2021-05-15 |
| Est. Completion | 2022-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04912024
The ClinicalTrials.gov registry entry for NCT04912024 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Outset Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System is the first listed.
NCT04912024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04912024 about?
NCT04912024 is a clinical study titled "Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study". Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.
What is the current status of trial NCT04912024?
This trial is currently completed. The enrollment target is 458 participants. The study started on 2021-05-15. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT04912024?
The interventions under investigation include: Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System (DEVICE), Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems (DEVICE).
Who is sponsoring clinical trial NCT04912024?
This trial is sponsored by Outset Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.